<DOC>
	<DOC>NCT00737360</DOC>
	<brief_summary>The purpose of this study is to determine whether TAS-106 is effective to patients with recurrent or metastatic head and neck cancer refractory to platinum based chemotherapy.</brief_summary>
	<brief_title>Phase II Study of TAS-106 to Treat Head and Neck Cancer</brief_title>
	<detailed_description />
	<mesh_term>Head and Neck Neoplasms</mesh_term>
	<criteria>Age 18 ≤ years old at study entry Histologically confirmed head and neck carcinoma Received prior platinum based regimen and developed disease progression or recurrence Measurable disease according to RECIST guidelines Radiological or clinical evidence of brain involvement or leptomeningeal disease ≥ grade 2 peripheral neuropathy History of another malignancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>